Search Medical Condition
Please enter condition
Please choose location
 

Hampstead, United Kingdom Clinical Trials

A listing of Hampstead, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (565) clinical trials

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

The drug being tested in this study is called IXAZOMIB. IXAZOMIB was being tested to treat people who have relapsed or Refractory Systemic Light Chain (AL) Amyloidosis. The study will enroll approximately 248 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two ...

Phase

0.32 miles

Learn More »

Safety and Biomarker Study of EPI-589 in Parkinson's Disease

This is a within-subject, controlled open-label study seeking to determine if EPI-589 can alter the biochemical signature of PD as assessed by peripheral blood and brain imaging biomarkers. Data will also be collected on disease-relevant clinical measures will be collected.

Phase

0.5 miles

Learn More »

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

The purpose of this study is to investigate the pharmacokinetics (PK), efficacy, and safety of rVIIa-FP (CSL689). The study will enroll approximately 54 male subjects, 12 to 65 years of age, with hemophilia types A or B who have developed inhibitors to FVIII or FIX. The study consists of 3 ...

Phase

0.5 miles

Learn More »

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects will be randomized to receive low or high dose vaccine, in the presence or absence of IC31® adjuvant, or to receive placebo or IC31® ...

Phase

0.5 miles

Learn More »

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two different delivery devices: injections using pump or rapid push.

Phase

0.5 miles

Learn More »

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Study design: randomized, double-blind, placebo-controlled, multicentre phase 2 proof-of-concept trial of IVA337 for the treatment DcSSc. The treatments are randomly assigned. The randomisation is stratified for background therapy to ensure even distribution of background therapies among treatment groups. There are 3 parallel treatment groups: placebo, IVA337 400mg bid and IVA337 ...

Phase

0.5 miles

Learn More »

A Multi-part Double Blind Study to Assess Safety Tolerability and Efficacy of LJN452 in PBC Patients

A multi-part study to assess safety, tolerability and efficacy of LJN452 in patients with primary biliary cholangitis

Phase

0.5 miles

Learn More »

A Single Escalating Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B With or Without Inhibitors

Investigate the safety, tolerability and pharmacokinetics of BAY 1093884 after Intravenous (IV) and subcutaneous (SC) administration of increasing single doses.

Phase

0.5 miles

Learn More »

Phase 4 Study to Evaluate the Effect of Velaglucerase Alfa (VPRIV ) on Patients With Type 1 Gaucher Disease Through the IV Administration of VPRIV Over 2 Years

To evaluate the effect of VPRIV® therapy on patients with type 1 Gaucher disease by measuring the change in the lumbar spine (LS) and bone mineral density (BMD) after 24 months of treatment.

Phase

0.5 miles

Learn More »

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. NOTE: Global recruitment is complete but enrollment is ongoing for the China sub-study. The Completion Date for the Primary Outcome Measure is expected in October 2018.

Phase

0.5 miles

Learn More »